The 4th Paris NASH Meeting was held July 5-6, 2018 at the Institut Pasteur in Paris, France. The meeting was co-organizated by Dr. Lawrence Serfaty, Hôpitaux Universitaires de Strasbourg, Dr. Arun Sanyal, Virginia Commonwealth University, and Dr. Veronica Miller, Forum for Collaborative Research

The materials from the 2-day meeting that have been made available can be found on the meeting website (https://paris-nash.org/materials), or below:

 

THURSDAY, JULY 5, 2018

• Welcome remarks
  Lawrence Serfaty (France)
• Inauguration Address
  Stanislas Pol (France)

SESSION 1 • NASH EPIDEMIOLOGY AND PUBLIC HEALTH

Chairs: Patrick Marcellin (France) and Michael Trauner (Austria)

• The value proposition of NASH therapy on the burden of disease related to obesity.
  Homie Razavi (USA)
• The evolution of NASH from childhood to adulthood.
  Joel Lavine (USA)
• What is needed to put NASH on the radar for WHO- lessons learned from viral hepatitis.
  Jean-Michel Pawlotsky (France) and Stanislas Pol (France)
• Discussion

SESSION 2 • CARDIO-METABOLIC MORBIDITY AND MORTALITY DUE TO NAFLD

Chairs: Scott Friedman (USA) and Fabio Marra (Italy)

• Does reversal of NASH reverse cardiovascular risk?
  Bart Staels (France)
• Is type 2 diabetes and NASH the same disease affecting different organs?
  Bertrand Cariou (France)
• Acceleration of cardiometabolic disease after liver transplantation for NASH.
  Mohammad Siddiqui (USA)
• Discussion

SESSION 3 • CLINICAL STATE OF THE ART LECTURE

Chair: Philippe Mathurin (France)

• The pathophysiological, clinical and regulatory implications of alcohol consumption in Non Alcoholic SteatoHepatitis.
  Arun Sanyal (USA)

SESSION 4 • PRECISION MEDICINE FOR NASH

Chairs: Quentin Anstee (United Kingdom) and Lawrence Serfaty (France)

• Molecular markers of disease progression in NASH.
  Jean-François Dufour (Switzerland)
• Phenotyping NAFLD based on whole body morphometry.
  Olof Dahlqvist Leinhard (Sweden)
• Phenotyping NAFLD based on the gut microbiome.
  Karim Dabbagh (USA)
• The potential use of iPSC to guide Precision Medicine for NASH.
  David Goldman (USA)
• Discussion

SESSION 5 • TECHNOLOGIC INNOVATIONS IN NASH

Chairs: Jean-Pierre Bronowicki (France) and Frank Tacke (Germany)

• Radiomics and imaging inflammation in solid organs.
  Richard Ehman (USA)
• The protease signature of NASH.
  Gabe Kwong (USA)
• Gut-based immunotherapy - implications for NASH.
  Yaron Ilan (Israel)
• Discussion

FRIDAY, JULY 6, 2018

SESSION 6 • NAFLD AND HCC

Chairs: Stanislas Pol (France) and Manuel Romero-Gómez (Spain)

• Clinical and Pathological characteristics of steatohepatitis HCC.
  Pierre Bedossa (France)
• Immune mechanisms in the genesis of HCC due to NASH.
  Frank Tacke (Germany)
• Epigenetic basis for NASH associated HCC.
  Igor Pogribny (USA)
• How will new therapies affect HCC development?
  Scott Friedman (USA)
• Discussion

SESSION 7 • PATIENT CENTERED APPROACH TO NASH

Chairs: Mohammad Siddiqui (USA) and Zobair Younossi (USA)

• Development of a patient reported outcomes instrument for NASH that meets regulatory standards.
  Maria-Magdalena Balp (Switzerland)
• The science and art of patient-engaged trial design.
  Donna Cryer (USA)
• The burden of cirrhosis on their caregivers.
  Jasmohan Bajaj (USA)
• Discussion

SESSION 8 • REGULATORY LANDSCAPE

Chair: Lawrence Serfaty (France)

• Regulatory Update.
  Veronica Miller (USA)
• Discussion

SESSION 9 • TRIAL DESIGN

Chairs: Veronica Miller (USA) and Arun Sanyal (USA)

• Master - protocols in NASH - challenges and opportunities.
  Raluca Pais (France)
• Learning from placebo responses in current trials to improve future trial design.
  Quentin Anstee (United Kingdom)
• Discussion

SESSION 10 • ROUND TABLE

Chairs: Arun Sanyal (USA) and Lawrence Serfaty (France)

• Building synergy between patient advocacy and drug development for NASH.
  Panelists: Quentin Anstee (United Kingdom), Donna Cryer (USA), Dean Hum (France), Omoro Omoighe (USA), Manuel Romero-Gómez (Spain), Aldo Trylesinski (United Kingdom), Marko Korenjak (Slovenia)